Core Insights - Daxor Corporation reported a strong financial performance for fiscal 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company has successfully transitioned to cash-flow positive operations in Q1 of 2025, excluding non-cash expenses [4] - Daxor is focused on launching its next-generation blood volume analyzer, which is expected to enhance clinical workflows and open new market opportunities [2] Financial Highlights - The net asset value (NAV) per share increased to 7.08 in 2023 [1] - Daxor signed 12 new accounts in 2024, resulting in a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - The company secured a 350,000 in grants from NIH and Launch Tennessee to support ongoing research and development [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - The company has performed over 65,000 tests at leading hospital centers across the U.S., significantly improving patient outcomes in various medical conditions [3] - Daxor is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [3]
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024